<DOC>
	<DOC>NCT01815827</DOC>
	<brief_summary>This open-label, parallel group study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of inclacumab in Japanese healthy volunteers compared to Caucasian healthy volunteers. Subjects will receive a single intravenous dose of inclacumab. Follow-up will be for up to 197 days.</brief_summary>
	<brief_title>A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male and female volunteers, 18 to 55 years of age, inclusive Healthy status as defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination Japanese subjects must have Japanese parents and grandparents who were born in Japan Caucasian subjects must have Caucasian parents and grandparents Body mass index (BMI) 18 30 kg/m2 inclusive Clinically significant abnormalities in laboratory test results (including positive test for HIV, hepatitis B and/or C), vital signs or ECGs Any confirmed significant allergic reactions against any drug, or multiple allergies (nonactive hay fever is acceptable) Smokes more than 5 cigarettes per day during the three months prior to study conduct Participation in an investigational drug or device study within 30 days or 5 halflives prior to screening Positive test for drugs of abuse Any suspicion of or history of alcohol and/or other substance abuse or addiction Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>